Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure
Open Access
- 15 May 2020
- Vol. 63 (9), 911-920
- https://doi.org/10.1111/myc.13104
Abstract
Background Candida glabrata is the third leading cause of candidaemia in Turkey; however, the data regarding antifungal resistance mechanisms and genotypic diversity in association with their clinical implication are limited. Objectives To assess genotypic diversity, antifungal susceptibility and mechanisms of drug resistance of C glabrata blood isolates and their association with patients' outcome in a retrospective multicentre study. Patients/Methods Isolates from 107 patients were identified by ITS sequencing and analysed by multilocus microsatellite typing, antifungal susceptibility testing, and sequencing of PDR1 and FKS1/2 hotspots (HSs). Results Candida glabrata prevalence in Ege University Hospital was twofold higher in 2014‐2019 than in 2005‐2014. Six of the analysed isolates had fluconazole MICs ≥ 32 µg/mL; of them, five harboured unique PDR1 mutations. Although echinocandin resistance was not detected, three isolates had mutations in HS1‐Fks1 (S629T, n = 1) and HS1‐Fks2 (S663P, n = 2); one of the latter was also fluconazole‐resistant. All patients infected with isolates carrying HS‐FKS mutations and/or demonstrating fluconazole MIC ≥ 32 µg/mL (except one without clinical data) showed therapeutic failure (TF) with echinocandin and fluconazole; seven such isolates were collected in Ege (n = 4) and Gulhane (n = 3) hospitals and six detected recently. Among 34 identified genotypes, none were associated with mortality or enriched for fluconazole‐resistant isolates. Conclusion Antifungal susceptibility testing should be supplemented with HS‐FKS sequencing to predict TF for echinocandins, whereas fluconazole MIC ≥ 32 µg/mL may predict TF. Recent emergence of C glabrata isolates associated with antifungal TF warrants future comprehensive prospective studies in Turkey.Keywords
Funding Information
- National Natural Science Foundation of China (31770161)
This publication has 61 references indexed in Scilit:
- Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012Journal of Clinical Microbiology, 2012
- The Presence of an FKS Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrataAntimicrobial Agents and Chemotherapy, 2012
- FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin TherapyAntimicrobial Agents and Chemotherapy, 2011
- Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007BMC Infectious Diseases, 2010
- Breakthrough Invasive Candidiasis in Patients on MicafunginJournal of Clinical Microbiology, 2010
- Novel FKS Mutations Associated with Echinocandin Resistance in Candida SpeciesAntimicrobial Agents and Chemotherapy, 2010
- Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant RecipientAntimicrobial Agents and Chemotherapy, 2010
- Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infectionsAmerican Journal of Infection Control, 2010
- Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata InfectionAntimicrobial Agents and Chemotherapy, 2008
- Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia TreatmentAntimicrobial Agents and Chemotherapy, 2008